Codexis Inc
4QK
Company Profile
Business description
Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.
Contact
200 Penobscot Drive
Redwood CityCA94063
USAT: +1 650 421-8100
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
146
Stocks News & Analysis
stocks
ASX major bank drives strong quarterly profit
Profit momentum remains robust yet shares overvalued.
stocks
Ask the analyst: What to expect in earnings season?
The key metrics that matter this earnings season.
stocks
ASX healthcare share remains undervalued ahead of earnings
Margin recovery remains the key driver for this ASX healthcare share.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,063.80 | 36.20 | 0.40% |
| CAC 40 | 8,406.06 | 33.78 | 0.40% |
| DAX 40 | 25,361.03 | 262.03 | 1.04% |
| Dow JONES (US) | 52,027.86 | 80.61 | 0.16% |
| FTSE 100 | 10,781.75 | 45.52 | 0.42% |
| HKSE | 25,207.18 | 243.95 | 0.98% |
| NASDAQ | 24,832.46 | 143.37 | -0.57% |
| Nikkei 225 | 64,931.19 | 320.04 | 0.50% |
| NZX 50 Index | 13,850.69 | 78.40 | 0.57% |
| S&P 500 | 7,390.13 | 21.85 | -0.29% |
| S&P/ASX 200 | 8,894.00 | 36.10 | 0.41% |
| SSE Composite Index | 3,858.25 | 44.05 | 1.15% |